¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"time factor"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
reticuloendothelial depressant factor
±×¹°³»Çǰè¾ïÁ¦ÀÎÀÚ, ¸Á»ó³»Çǰè¾ïÁ¦ÀÎÀÚ
rheumatoid factor
·ù¸¶Æ¼½ºÀÎÀÚ
risk factor
À§ÇèÀÎÀÚ
roentgen-to-rad conversion factor
·ÛÆ®°Õ´ë·¡µåº¯È¯°è¼ö
somatotropin release inhibiting factor
¼ºÀåÈ£¸£¸óºÐºñ¾ïÁ¦ÀÎÀÚ
spreading factor
È®»êÀÎÀÚ
stable factor
¾ÈÁ¤ÀÎÀÚ
scatter factor
»ê¶õ°è¼ö
stroma factor
¹öÆÀÁúÀÎÀÚ, °£ÁúÀÎÀÚ
sunprotective factor
Àϱ¤º¸È£Áö¼ö
sebotropic factor
Áö·çÃËÁøÀÎÀÚ
safety factor
¾ÈÀü°è¼ö
skin vascular permeability factor
ÇǺÎÇ÷°üÅõ°úÀÎÀÚ
vascular endothelial growth factor
Ç÷°ü³»ÇǼºÀåÀÎÀÚ
vascular permeability factor
Ç÷°üÅõ°úÀÎÀÚ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
relaxing factor
ÀÌ¿ÏÀÎÀÚ
resistance factor
³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
resistancetransfer factor
³»¼ºÀü´ÞÀÎÀÚ
reticuloendothelial depressant factor
¼¼¸Á³»Çǰè¾ïÁ¦ÀÎÀÚ, ±×¹°³»Çǰè¾ïÁ¦ÀÎÀÚ
rheumatoid factor
·ù¸¶Æ¼½ºÀ¯»çÀÎÀÚ
risk factor
À§ÇèÀÎÀÚ
roentgen-to-rad conversion factor
·ÛÆ®°Õ¶óµåº¯È¯°è¼ö
safety factor
¾ÈÀü°è¼ö
scatter factor
»ê¶õ°è¼ö
sebotropic factor
Áö·çÃËÁøÀÎÀÚ
skin vascular permeability factor
ÇǺÎÇ÷°üÅõ°úÀÎÀÚ
somatotropin release inhibiting factor
¼ºÀåÈ£¸£¸óÀ¯¸®¾ïÁ¦ÀÎÀÚ
spreading factor
È®»êÀÎÀÚ
stable factor
¾ÈÁ¤ÀÎÀÚ
stroma factor
¹öÆÀÁúÀÎÀÚ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
4
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
realization factor
½ÇÇöÀÎÀÚ(ãùúÞì×í).
recruitment factor
´©°¡¿äÀÎ(׫ʥé©ì×).
reducing factor
ȯ¿øÀÎÀÚ.
relaxing factor
ÀÌ¿ÏÀÎÀÚ(ì¬èÐì×í).
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
time-motion curve
½Ã°£-¿îµ¿ °î¼± (ãÁÊà-ê¡ÔÑ ÍØàÊ)
time-resolved fluorescent immunoassay
½Ã°£Â÷Çü±¤¸é¿ªÃøÁ¤(¹ý)
time-velocity integral
½Ã°£-¼Óµµ Á¤¼ö (ãÁÊà-áÜÓø ïÚâ¦)
transit time
õÀ̽ð£, Åë°ú½Ã°£
transit time
ÀüÀ̽ð£.
transverse relaxation time
ȾÃà À̿Ͻð£
travel time
ÁÖÇà½Ã°£.
turnaround time monitoring
Àü¼øÈ¯½Ã°£°¨½Ã
utility time
ÀÌ¿ë½Ã(°£)(ì¦éÄãÁÊà).
utilization time
ÀÌ¿ë½Ã°£(ì¦éÄãÁÊà).
ventricular activation time
½É½ÇÈïºÐ½Ã°£(ãýãøýéÝÇãÁÊà).
voiding time
¹è´¢½Ã°£
whole blood clot lysis time
ÀüÇ÷Ç÷º´À¶ÇØ<--¿ëÇØ>½Ã°£
working time
³ë·Â±â(ËÈËçË»), ³ë·Â½Ã°£(ËÈËçËà˧).
absorbed dose conversion factor
Èí¼ö¼±·®º¯È¯°è¼ö
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½